|Trade names||Floxapen, others|
|By mouth, IM, IV, intrapleural, intraarticular|
|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||0.75–1 hour|
|Chemical and physical data|
|Molar mass||453.87 g·mol−1|
|3D model (JSmol)|
Flucloxacillin, also known as floxacillin, is an antibiotic used to treat skin infections, external ear infections, infections of leg ulcers, diabetic foot infections, and infection of bone. It may be used together with other medications to treat pneumonia, and endocarditis. It may also be used prior to surgery to prevent Staphylococcus infections. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA). It is taken by mouth or given by injection into a vein or muscle.
Common side effects include an upset stomach. Other side effects may include muscle or joint pains, shortness of breath, and liver problems. It appears to be safe during pregnancy and breastfeeding. It should not be used in those who are allergic to penicillin. It is a narrow-spectrum beta-lactam antibiotic of the penicillin class. It is similar in effect to cloxacillin and dicloxacillin, being active against penicillinase forming bacteria.
Flucloxacillin was patented in 1961. It is available as a generic medication. In the United Kingdom 100 capsules of 250 mg costs the NHS less than 20 pounds. It is not commonly used in the United States or Canada as of 2011.
Flucloxacillin is used for both staphylococcal and streptococcal skin infections. These include folliculitis, carbuncles, impetigo, ecthyma, cellulitis, erysipelas, necrotising fasciitis, and infections of skin conditions such as eczema, scabies, ulcers and acne. Due to the widespread belief that dual-therapy is needed to cover both Staphylococcus and Streptococcus in cellulitis, flucloxacillin is sometimes given with the addition of benzylpenicillin for more severe cellulitis. However, support for this practice has lessened since findings in a study published in the Emergency Medicine Journal in 2005 did not show this combination to give additional clinical benefit. In the UK, using flucloxacillin alone is the first choice for treating cellulitis. Some other countries vary.
Infections of leg ulcers can be treated with 500mg to 1000mg oral flucloxacillin four times a day for seven days, or intravenously at 1000mg to 2000mg 4 times a day. With diabetic foot infections the dose is adjusted according to whether the infection appears mild, moderate or severe.
Despite having a lower than optimum drug penetration into bone ratio of 10-20%, flucloxacillin appears effective in treating osteomyelitis. Up to 2 grams 4 times a day by slow injection into a vein may be given.
It may be used in combination with other antibiotics to treat pneumonia and can be used to prevent infection before surgery, particularly heart, lung, or bone surgery. When used to treat endocarditis, in combination with other antibiotics or alone, the dose of flucloxacillin may need to exceed the 2 grams 4 times a day in people over 85 kilograms.
Despite flucloxacillin being insensitive to beta-lactamases, some organisms have developed resistance to it and other narrow-spectrum β-lactam antibiotics including methicillin. Such organisms include methicillin-resistant Staphylococcus aureus, which has developed resistance to flucloxacillin and other penicillins by having an altered penicillin-binding protein.
|Age category||Typical dosage|
|1 month to 1 year||62.5 - 125mg 4 times/day|
|2 - 9 years||125 - 250mg 4 times/day|
|10 - 17 years||250 - 500mg 4 times/day|
|Adult||250 - 500mg 4 times/day|
The typical dose for adults is 250 mg to 500 mg 4 times per day by mouth. Doses by injection into veins in adults may be given at 1 to 2 grams every 6 hours for more severe infections or deep seated infections such as osteomyelitis.
Common side effects associated with the use of flucloxacillin include: diarrhoea, nausea, rash, urticaria, pain and inflammation at injection site, superinfection (including candidiasis), allergy, and transient increases in liver enzymes and bilirubin.
Rarely, in less than 1 in 1,000 people, cholestatic jaundice (also referred to as cholestatic hepatitis) has been associated with flucloxacillin therapy. It may appear as pale stool with dark urine, and yellowish eyes and skin. The reaction may occur up to several weeks after treatment has stopped, and takes weeks to resolve. The estimated incidence is one in 15,000 exposures, and is more frequent in people over the age of 55, females, and those with a treatment duration of longer than two weeks.
Flucloxacillin is contraindicated in those with a previous history of allergy to penicillins, cephalosporins, or carbapenems. It should also not be used in the eye, or administered to those with a history of cholestatic hepatitis associated with the use of dicloxacillin or flucloxacillin.
It should be used with caution in the elderly, patients with renal impairment where a reduced dose is required, and those with hepatic impairment, due to the risk of cholestatic hepatitis.
It should be taken on an empty stomach, one half to one hour before food, as absorption is reduced when taken with food, though some studies suggest that this does not compromise flucloxacillin plasma concentrations in most circumstances.
Flucloxacillin can reduce the excretion of methotrexate, potentially resulting in a risk of methotrexate toxicity. The level of flucloxacillin in the blood may rise in kidney failure and with the use of probenecid.
Mechanism of action
Like other β-lactam antibiotics, flucloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria.
Flucloxacillin is more acid-stable than many other penicillins and can be given orally, in addition to parenteral routes. However, like methicillin, it is less potent than benzylpenicillin against non-β-lactamase-producing Gram-positive bacteria.
Flucloxacillin has similar pharmacokinetics, antibacterial activity, and indications to dicloxacillin, and the two agents are considered interchangeable. It is reported to have higher, though rare, incidence of severe hepatic adverse effects than dicloxacillin, but a lower incidence of renal adverse effects.
Flucloxacillin is insensitive to beta-lactamase (also known as penicillinase) enzymes secreted by many penicillin-resistant bacteria. The presence of the isoxazolyl group on the side chain of the penicillin nucleus facilitates the β-lactamase resistance, since they are relatively intolerant of side chain steric hindrance. Thus, it is able to bind to penicillin-binding proteins and inhibit peptidoglycan crosslinking, but is not bound by or inactivated by β-lactamases.
Flucloxacillin was developed in the 1960s following an increase in penicillin-resistant (beta-lactamase producing) staphylococcal infections due to the widespread use of benzylpenicillin by 1960. All the natural penicillins and first semi-synthetic penicillins were destroyed by staphylococcal beta-lactamase, leading Beecham (later GlaxoSmithKline) to search for more stable antibiotics. By 1962, a series of similarly structured acid-stable penicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), with the potential for being taken by mouth, were developed. Flucloxacillin and dicloxacillin showed particular stability against the beta-lactamase enzyme of Staph. aureus and could withstand acid. Beecham further developed cloxacillin and popularised flucloxacillin in the UK, while Bristol Laboratories concentrated on marketing oxacillin and dicloxacillin in the United States, leading to the difference in use in both countries. Flucloxacillin was first marketed in Europe in the 1970s.
Society and culture
Both the oral and intravenous preparations of flucloxacillin are inexpensive and are available as the sodium salt flucloxacillin sodium, in capsules (250 or 500 mg), oral suspensions (125 mg/5 ml or 250 mg/5 ml), and injections (powder for reconstitution, 250, 500, 1000 and 2000 mg per vial). In the UK, it is the second most commonly prescribed antibiotic in primary care, constituting 4.0 million prescriptions in 2018.
Flucloxacillin is not commonly used in the United States or Canada as of 2011. In several other countries however, it is supplied under a variety of trade names including Floxapen, Flopen, Flubex, Flupen, Phylopen, and Staphylex.
- "Flucloxacillin". Drugs.com. Retrieved 11 December 2020.
- Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 188–189. ISBN 978-0-7020-7442-4.
- BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 582-587. ISBN 978-0-85711-369-6.CS1 maint: date format (link)
- "Methicillin-resistant Staphylococcus aureus (MRSA)" (PDF). NHS. 2005. p. 3. Retrieved 11 December 2020.
- Wu, Alan H. B.; Yeo, Kiang-Teck J. (2011). Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. Springer Science & Business Media. ISBN 978-1-60761-283-4.
- Weller, Richard B.; Hunter, Hamish J. A.; Mann, Margaret W. (2014). Clinical Dermatology. John Wiley & Sons. p. 411. ISBN 978-1-118-85097-8.
- Alapi, Erika M.; Fischer, Jánus (2006). "Part III. Table of Selected Analogue Classes". In Fischer, János; Ganellin, C. Robin (eds.). Analogue-based Drug Discovery. Wiley-VCH. p. 491. ISBN 978-3-527-31257-3.
- Stanway, Amy. "Streptococcal skin infection - DermNet New Zealand". www.dermnetnz.org.
- Gould, Kate (2016). "1.6 Applied surgical microbiology". In Thomas, William E. G.; Reed, Malcolm W. R.; Wyatt, Michael G. (eds.). Oxford Textbook of Fundamentals of Surgery. Oxford University Press. pp. 176–177. ISBN 978-0-19-966554-9.
- "Flucloxacillin 125mg/5ml Oral solution - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 16 December 2020.
- Leman, P; Mukherjee, D (2005). "Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: A randomised controlled trial". Emergency Medicine Journal. 22 (5): 342–6. doi:10.1136/emj.2004.019869. PMC 1726763. PMID 15843702.
- Sarkar, Rashmi; Nair, Vivek; Sinha, Surabhai; Garg, Vijay K.; Rodriguez, David A. (2011). "7. Infectious diseases". In Taylor, Susan C.; Gathers, Raechele C.; Callender, Valerie D.; Rodriguez, David A.; Badreshia-Bansal, Sonia (eds.). Treatments for Skin of Color E-Book. Saunders Elsevier. p. 121. ISBN 978-1-4377-0859-2.
- Cox, Neil H. (2009). "41. Streptococcal Cellulitis/Erysipelas of the lower leg". In Williams, Hywel; Bigby, Michael; Diepgen, Thomas; Herxheimer, Andrew; Naldi, Luigi; Rzany, Berthold (eds.). Evidence-Based Dermatology (2nd ed.). Blackwell Publishing. p. 409. ISBN 978-1-4051-4518-3.
- Sullivan, Tadhg; de Barra, Eoghan (April 2018). "Diagnosis and management of cellulitis". Clinical Medicine. 18 (2): 160–163. doi:10.7861/clinmedicine.18-2-160. ISSN 1470-2118. PMC 6303460. PMID 29626022.
- Preiss, Helga; Kriechling, Philipp; Montrasio, Giulia; Huber, Tanja; Janssen, İmke; Moldovan, Andreea; Lipsky, Benjamin A.; Uçkay, İlker (1 January 2020). "Oral Flucloxacillin for Treating Osteomyelitis: A Narrative Review of Clinical Practice". Journal of Bone and Joint Infection. 5 (1): 16–24. doi:10.7150/jbji.40667. ISSN 2206-3552. PMC 7045523. PMID 32117685.
- Thabit, Abrar K.; Fatani, Dania F.; Bamakhrama, Maryam S.; Barnawi, Ola A.; Basudan, Lana O.; Alhejaili, Shahad F. (1 April 2019). "Antibiotic penetration into bone and joints: An updated review". International Journal of Infectious Diseases. 81: 128–136. doi:10.1016/j.ijid.2019.02.005. ISSN 1201-9712. PMID 30772469.
- Parveen Kumar; Michael L Clark (2011). "9. Drugs in Rheumatology". Kumar & Clark's Medical Management and Therapeutics - E-Book. Elsevier. p. 322. ISBN 978-0-7020-2765-9.
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
- "Flucloxacillin: antibiotic to treat infections". nhs.uk. November 27, 2018.
- "New Zealand Consumer Medicine Information" (PDF). medsafe.govt.nz.
- Gardiner, Sharon; Drennan, Phillip; Begg, Ronald (2018). "In healthy volunteers, taking flucloxacillin with food does not compromise effective plasma concentrations in most circumstances". PLOS ONE. 13 (7): e0199370. Bibcode:2018PLoSO..1399370G. doi:10.1371/journal.pone.0199370. PMC 6042703. PMID 30001392.
- "Flucloxacillin sodium salt". pubchem.ncbi.nlm.nih.gov. PubChem at the National Institutes of Health. Retrieved 13 December 2020.
- "LiverTox: Clinical and Research Information on Drug-Induced Liver Injury". National Institute of Diabetes and Digestive and Kidney Diseases. October 21, 2012. PMID 31643176 – via PubMed.
- White, Richard J. (2010). Fischer, János; Ganellin, C. Robin (eds.). Analogue-based Drug Discovery II. Wiley-VCH. p. 11. ISBN 978-1-4614-1399-8.
- Page, Malcolm G. P. (2012). "3. Beta-Lactam Antibiotics". In Dougherty, Thomas J.; Pucci, Michael J. (eds.). Antibiotic Discovery and Development. Springer. pp. 86–88. ISBN 978-1-4614-1399-8.
- Greenwood, David (2008). "4. Wonder Drugs". Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford: Oxford University Press. p. 124. ISBN 978-0-19-953484-5.
- Sutherland R, Croydon EA, Rolinson GN (November 1970). "Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin". British Medical Journal. 4 (5733): 455–60. doi:10.1136/bmj.4.5733.455. PMC 1820086. PMID 5481218.
- "Search Results - Flucloxacillin". www.medicines.org.uk. Retrieved 16 December 2020.
- Chaplin, Steve (4 September 2020). "NICE on antimicrobial prescribing for leg ulcer infection". Prescriber. 31 (7–8): 27–30. doi:10.1002/psb.1858. ISSN 1931-2253. Retrieved 6 February 2021.